Advanced therapies and the outer limits of DNA regulation: new horizons for patents or a scaffold too far?

Abstract

This Regulation seeks to regulate existing and future advanced therapy medicinal products intended for the market in Member States, being either prepared industrially or manufactured by a method involving an industrial process, and introduces additional provisions to those laid down in the pharmaceutical legislation Directive 2001/83.